Details of the Drug

General Information of Drug (ID: DM0LPI9)

Drug Name
Netarsudil
Synonyms
UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4
Indication
Disease Entry ICD 11 Status REF
Open-angle glaucoma 9C61 Approved [1]
Glaucoma/ocular hypertension 9C61 Phase 2 [2]
Affected Organisms
Humans and other mammals
ATC Code
S01EX05: Netarsudil
S01EX: Other antiglaucoma preparations
S01E: ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 453.5
Logarithm of the Partition Coefficient (xlogp) 4.6
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 175 minutes [3]
Metabolism
The drug is metabolized via the esterases in the eye to its active metabolite, netarsudil-M1 (or AR-13503) [3]
Chemical Identifiers
Formula
C28H27N3O3
IUPAC Name
[4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
Canonical SMILES
CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
InChI
InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
InChIKey
OURRXQUGYQRVML-AREMUKBSSA-N
Cross-matching ID
PubChem CID
66599893
ChEBI ID
CHEMBL4594250
CAS Number
1254032-66-0
UNII
W6I5QDT7QI
DrugBank ID
DB13931
TTD ID
D04WYX
ACDINA ID
D01281
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Modulator [2]
Rho-associated protein kinase (ROCK) TTMQO60 NOUNIPROTAC Modulator [2]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Open-angle glaucoma
ICD Disease Classification 9C61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Boric acid E00152 7628 Antimicrobial preservative; Buffering agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Netarsudil 0.2mg/ml solution 0.2mg/ml Solution Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
3 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2017 Jun 13. doi: 10.1089/jop.2017.0023.